GB9113802D0 - Medicaments - Google Patents

Medicaments

Info

Publication number
GB9113802D0
GB9113802D0 GB919113802A GB9113802A GB9113802D0 GB 9113802 D0 GB9113802 D0 GB 9113802D0 GB 919113802 A GB919113802 A GB 919113802A GB 9113802 A GB9113802 A GB 9113802A GB 9113802 D0 GB9113802 D0 GB 9113802D0
Authority
GB
United Kingdom
Prior art keywords
medicaments
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
GB919113802A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Ltd
Original Assignee
SmithKline Beecham Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10697363&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GB9113802(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by SmithKline Beecham Ltd filed Critical SmithKline Beecham Ltd
Priority to GB919113802A priority Critical patent/GB9113802D0/en
Publication of GB9113802D0 publication Critical patent/GB9113802D0/en
Priority to UA93002251A priority patent/UA41254C2/uk
Priority to PCT/GB1992/001082 priority patent/WO1993000086A1/en
Priority to BR9206237A priority patent/BR9206237A/pt
Priority to AU19775/92A priority patent/AU652842C/en
Priority to CA002113726A priority patent/CA2113726C/en
Priority to DE2002199042 priority patent/DE10299042I2/de
Priority to KR1019930704055A priority patent/KR100251571B1/ko
Priority to AT92912379T priority patent/ATE170746T1/de
Priority to SG1996004938A priority patent/SG47877A1/en
Priority to US08/167,846 priority patent/US5464864A/en
Priority to PL92311304A priority patent/PL171034B1/pl
Priority to SK1685-98A priority patent/SK280907B6/sk
Priority to HK98116054.2A priority patent/HK1014669B/en
Priority to DE69226953T priority patent/DE69226953T2/de
Priority to CZ961505A priority patent/CZ150596A3/cs
Priority to EP92912379A priority patent/EP0591280B1/en
Priority to CS932861A priority patent/CZ282083B6/cs
Priority to SK1319-93A priority patent/SK280905B6/sk
Priority to PL92307118A priority patent/PL169410B1/pl
Priority to DK92912379T priority patent/DK0591280T3/da
Priority to HU9303731A priority patent/HU218907B/hu
Priority to CZ961506A priority patent/CZ150696A3/cs
Priority to PL92301883A priority patent/PL169392B1/pl
Priority to RU93058534A priority patent/RU2137474C1/ru
Priority to JP51108692A priority patent/JP3261502B2/ja
Priority to SK1054-98A priority patent/SK280906B6/sk
Priority to PT100620A priority patent/PT100620B/pt
Priority to NZ243288A priority patent/NZ243288A/en
Priority to MA22853A priority patent/MA22563A1/fr
Priority to ZA924658A priority patent/ZA924658B/xx
Priority to TW081104991A priority patent/TW214544B/zh
Priority to IL117104A priority patent/IL117104A/xx
Priority to CN92108831A priority patent/CN1034072C/zh
Priority to IL11710596A priority patent/IL117105A0/xx
Priority to IL117105A priority patent/IL117105A/en
Priority to IL102322A priority patent/IL102322A/xx
Priority to APAP/P/1992/000403A priority patent/AP344A/en
Priority to MX9203444A priority patent/MX9203444A/es
Priority to SI9200125A priority patent/SI9200125B/sl
Priority to IE206292A priority patent/IE922062A1/en
Priority to SA92130141A priority patent/SA92130141B1/ar
Priority to NO934759A priority patent/NO304774B1/no
Priority to FI935842A priority patent/FI103967B1/fi
Priority to US08/442,720 priority patent/US5827871A/en
Priority to US08/442,719 priority patent/US5637611A/en
Priority to BR1100460-6A priority patent/BR1100460A/pt
Priority to LU90939C priority patent/LU90939I2/fr
Priority to NL300103C priority patent/NL300103I2/nl
Priority to NO2005011C priority patent/NO2005011I2/no
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/82—Carbazoles; Hydrogenated carbazoles
    • C07D209/88—Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
GB919113802A 1991-06-26 1991-06-26 Medicaments Pending GB9113802D0 (en)

Priority Applications (50)

Application Number Priority Date Filing Date Title
GB919113802A GB9113802D0 (en) 1991-06-26 1991-06-26 Medicaments
UA93002251A UA41254C2 (uk) 1991-06-26 1992-06-17 ПОХІДНЕ ТЕТРАГІДРОКАРБАЗОЛУ АБО ЙОГО СІЛЬ, СОЛЬВАТ АБО ГІДРАТ ЯК АГОНІСТ 5-НТ<sub>1</sub>-ПОДІБНОГО РЕЦЕПТОРА, СПОСІБ ЇХ ОДЕРЖАННЯ ТА ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ
PCT/GB1992/001082 WO1993000086A1 (en) 1991-06-26 1992-06-17 Use of tetrahydrocarbazone derivatives as 5ht1 receptor agonists
BR9206237A BR9206237A (pt) 1991-06-26 1992-06-17 Uso de derivados de tetrahidrocarbazole como receptores agonistas 5-HT1.
AU19775/92A AU652842C (en) 1991-06-26 1992-06-17 Use of tetrahydrocarbazone derivatives as 5HT1 receptor agonists
CA002113726A CA2113726C (en) 1991-06-26 1992-06-17 Use of tetrahydrocarbazone derivatives as 5ht1 receptor agonists
DE2002199042 DE10299042I2 (de) 1991-06-26 1992-06-17 Verwendung von Tetrahydrocarbazolderivaten als 5HT1-Rezeptor-agonisten.
KR1019930704055A KR100251571B1 (ko) 1991-06-26 1992-06-17 5-ht₁수용체 효능제로서의 테트라하이드로카르바죤 유도체의 용도
AT92912379T ATE170746T1 (de) 1991-06-26 1992-06-17 Verwendung von tetrahydrocarbazolderivaten als 5ht1-rezeptor-agonisten
SG1996004938A SG47877A1 (en) 1991-06-26 1992-06-17 Use of tetrahydrocarbazone derivatives as 5HT receptor agonists
US08/167,846 US5464864A (en) 1991-06-26 1992-06-17 Use of tetrahydrocarbazone derivatives as 5HT1 receptor agonists
PL92311304A PL171034B1 (en) 1991-06-26 1992-06-17 Method of obtaining novel derivatives of tetrahydrocarbazole
SK1685-98A SK280907B6 (sk) 1991-06-26 1992-06-17 Deriváty tetrahydrokarbazolu, spôsob ich prípravy a farmaceutický prípravok s ich obsahom
HK98116054.2A HK1014669B (en) 1991-06-26 1992-06-17 Use of tetrahydrocarbazole derivatives as 5ht1-receptor agonists
DE69226953T DE69226953T2 (de) 1991-06-26 1992-06-17 Verwendung von tetrahydrocarbazolderivaten als 5ht1-rezeptor-agonisten
CZ961505A CZ150596A3 (en) 1991-06-26 1992-06-17 Tetrahydrocarbazole derivatives, process of their preparation and pharmaceutical compositions containing thereof
EP92912379A EP0591280B1 (en) 1991-06-26 1992-06-17 Use of tetrahydrocarbazole derivatives as 5ht1-receptor agonists
CS932861A CZ282083B6 (cs) 1991-06-26 1992-06-17 Použití tetrahydrokarbazonových derivátů jako agonistů 5HT1-receptorů
SK1319-93A SK280905B6 (sk) 1991-06-26 1992-06-17 3-metylamino-6-karboxamido-1,2,3,4-tetrahydrokarbazol, spôsob jeho prípravy, farmaceutický prípravok s jeho obsahom a jeho použitie
PL92307118A PL169410B1 (pl) 1991-06-26 1992-06-17 Sposób wytwarzania nowych pochodnych tetrahydrokarbazolu PL PL PL PL PL PL PL PL
DK92912379T DK0591280T3 (da) 1991-06-26 1992-06-17 Anvendelse af tetrahydrocarbazolderivater som 5HT1-receptoragonister
HU9303731A HU218907B (hu) 1991-06-26 1992-06-17 Eljárás hatóanyagként tetrahidrokarbazol-származékokat tartalmazó gyógyszerkészítmények előállítására, és eljárás a hatóanyagok egy csoportjának előállítására
CZ961506A CZ150696A3 (en) 1991-06-26 1992-06-17 Tetrahydrocarbazole derivatives, process of their preparation and pharmaceutical compositions containing thereof
PL92301883A PL169392B1 (pl) 1991-06-26 1992-06-17 Sposób wytwarzania nowych pochodnych tetrahydrokarbazolu Twórcy wynalazku:Francis D. King, Harlow, GB Laramie M. Gaster, Harlow, GB Alberto J. Kaumann, Welwyn, GB Rodney Ch. Young, Welwyn, GB PL PL PL PL PL PL PL PL
RU93058534A RU2137474C1 (ru) 1991-06-26 1992-06-17 Способ лечения состояния, в котором показан 5нтi-подобный агонист, производное тетрагидрокарбазола, способ его получения, фармацевтическая композиция, проявляющая активность агониста 5нтi-подобных рецепторов
JP51108692A JP3261502B2 (ja) 1991-06-26 1992-06-17 ５ｈｔ１レセプターアゴニストとしてのテトラヒドロカルバゾン誘導体の使用
SK1054-98A SK280906B6 (sk) 1991-06-26 1992-06-17 Použitie tetrahydrokarbazolových derivátov
PT100620A PT100620B (pt) 1991-06-26 1992-06-24 Derivados de tetra-hidrocarbazol, seu uso e preparacao e composicoes farmaceuticas que os contem
NZ243288A NZ243288A (en) 1991-06-26 1992-06-24 6-substituted-1,2,3,4-tetrahydrocarbazol-3-ylamines and pharmaceutical compositions thereof
MA22853A MA22563A1 (fr) 1991-06-26 1992-06-24 Procede de preparation de derives de tetrahydrocarbazole
ZA924658A ZA924658B (en) 1991-06-26 1992-06-24 Medicaments
TW081104991A TW214544B (enExample) 1991-06-26 1992-06-25
IL117104A IL117104A (en) 1991-06-26 1992-06-25 Tetrahydrocarbazole derivatives, process for their preparation and pharmaceutical compositions containing them
CN92108831A CN1034072C (zh) 1991-06-26 1992-06-25 四氢咔唑衍生物的制备方法
IL11710596A IL117105A0 (en) 1991-06-26 1992-06-25 Tetrahydrocarbazole derivatives process for their preparation and pharmaceutical compositions containing them
IL117105A IL117105A (en) 1991-06-26 1992-06-25 Tetrahydrocarbazole derivatives, process for their preparation and pharmaceutical compositions containing them
IL102322A IL102322A (en) 1991-06-26 1992-06-25 Tetrahydrocarbazole derivatives for use as 5-ht1-like agonist medicaments
APAP/P/1992/000403A AP344A (en) 1991-06-26 1992-06-25 Tetrahydrocarbazole derivatives and their use as 5-HT1-like receptor
MX9203444A MX9203444A (es) 1991-06-26 1992-06-26 Medicamentos.
SI9200125A SI9200125B (en) 1991-06-26 1992-06-26 Tetrahydrocarbazone derivatives used as medicaments
IE206292A IE922062A1 (en) 1991-06-26 1992-07-01 Medicaments
SA92130141A SA92130141B1 (ar) 1991-06-26 1992-10-04 مشتقات رباعي هيدروكربازول teterahydrocarbazole كعوامل مساعدة لمستقبل
NO934759A NO304774B1 (no) 1991-06-26 1993-12-23 Tetrahydrokarbazolderivater, farmas÷ytiske blandinger inneholdende slike og anvendelse av disse derivater
FI935842A FI103967B1 (fi) 1991-06-26 1993-12-23 Menetelmä tetrahydrokarbatsonijohdannaisten valmistamiseksi
US08/442,720 US5827871A (en) 1991-06-26 1995-05-15 Medicaments 1,2,3,4-tetrahydrocarbazoles and 5-HT1 agonist use thereof
US08/442,719 US5637611A (en) 1991-06-26 1995-05-15 Medicaments
BR1100460-6A BR1100460A (pt) 1991-06-26 1997-05-06 Uso de derivados de tetrahidrocarbazole como receptores agonistas 5-ht1
LU90939C LU90939I2 (fr) 1991-06-26 2002-07-24 3-Methtylamino-6carboxamido-1,2,3,4-tetrahhydrocarbazole (frovatriptan) et ses sels solvates et hydrates
NL300103C NL300103I2 (nl) 1991-06-26 2002-10-14 Toepassing van tetrahydrocarbazoolderivaten als 5HT1-receptoragonisten.
NO2005011C NO2005011I2 (no) 1991-06-26 2005-05-03 Frovatriptan

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB919113802A GB9113802D0 (en) 1991-06-26 1991-06-26 Medicaments

Publications (1)

Publication Number Publication Date
GB9113802D0 true GB9113802D0 (en) 1991-08-14

Family

ID=10697363

Family Applications (1)

Application Number Title Priority Date Filing Date
GB919113802A Pending GB9113802D0 (en) 1991-06-26 1991-06-26 Medicaments

Country Status (34)

Country Link
US (2) US5464864A (enExample)
EP (1) EP0591280B1 (enExample)
JP (1) JP3261502B2 (enExample)
KR (1) KR100251571B1 (enExample)
CN (1) CN1034072C (enExample)
AP (1) AP344A (enExample)
AT (1) ATE170746T1 (enExample)
BR (2) BR9206237A (enExample)
CA (1) CA2113726C (enExample)
CZ (3) CZ282083B6 (enExample)
DE (2) DE69226953T2 (enExample)
DK (1) DK0591280T3 (enExample)
FI (1) FI103967B1 (enExample)
GB (1) GB9113802D0 (enExample)
HU (1) HU218907B (enExample)
IE (1) IE922062A1 (enExample)
IL (4) IL117105A (enExample)
LU (1) LU90939I2 (enExample)
MA (1) MA22563A1 (enExample)
MX (1) MX9203444A (enExample)
NL (1) NL300103I2 (enExample)
NO (2) NO304774B1 (enExample)
NZ (1) NZ243288A (enExample)
PL (3) PL169392B1 (enExample)
PT (1) PT100620B (enExample)
RU (1) RU2137474C1 (enExample)
SA (1) SA92130141B1 (enExample)
SG (1) SG47877A1 (enExample)
SI (1) SI9200125B (enExample)
SK (3) SK280907B6 (enExample)
TW (1) TW214544B (enExample)
UA (1) UA41254C2 (enExample)
WO (1) WO1993000086A1 (enExample)
ZA (1) ZA924658B (enExample)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9211277D0 (en) 1992-05-28 1992-07-15 Glaxo Group Inc Pharmaceutical compositions
GB9226530D0 (en) * 1992-12-21 1993-02-17 Smithkline Beecham Plc Compounds
GB9226566D0 (en) * 1992-12-21 1993-02-17 Smithkline Beecham Plc Compounds
US5616603A (en) * 1995-05-26 1997-04-01 Smithkline Beecham Plc Enantiomers of carbazole derivatives as 5-HT1 -like agonists
US5618948A (en) * 1995-05-26 1997-04-08 Smithkline Beecham P.L.C. Process for preparing an enantiomer of a carbazole derivative
EP0749962B1 (en) * 1995-06-23 2000-11-02 Eli Lilly And Company 6-substituted-1,2,3,4-tetrahydro-9H-carbazoles and 7-substituted-10H-cyclohepta(7,6-B)indoles
US5917054A (en) * 1995-07-18 1999-06-29 Smithkline Beecham P.L.C. Process for preparing enantiomers of carbazole derivatives as 5-HT1 -like agonists
US5708187A (en) * 1996-06-27 1998-01-13 Eli Lilly And Company 6-substituted-1,2,3,4-tetrahydro-9H-carbazoles and 7-substituted-10H-cyclohepta 7,6-B!indoles: New 5-HT1F agonists
US5891885A (en) * 1996-10-09 1999-04-06 Algos Pharmaceutical Corporation Method for treating migraine
GB9723061D0 (en) * 1997-10-31 1998-01-07 Vanguard Medica Ltd Medicaments
US7189753B1 (en) 1997-11-06 2007-03-13 Cady Roger K Preemptive prophylaxis of migraine
US6066092A (en) * 1997-11-06 2000-05-23 Cady; Roger K. Preemptive prophylaxis of migraine device and method
GB9808069D0 (en) * 1998-04-16 1998-06-17 Vanguard Medica Ltd Novel processes
GB9817911D0 (en) * 1998-08-17 1998-10-14 Vanguard Medica Ltd New use
US6685951B2 (en) 2001-07-05 2004-02-03 R. T. Alamo Ventures I, Inc. Administration of dihydroergotamine as a sublingual spray or aerosol for the treatment of migraine
US20030198669A1 (en) * 2001-07-05 2003-10-23 R.T. Alamo Ventures I, Llc Compositions and methods for rapid dissolving formulations of dihydroergotamine and caffeine for the treatment of migraine
US20030017175A1 (en) * 2001-07-05 2003-01-23 R.T. Alamo Ventures I, Inc. Sublingual administration of dihydroergotamine for the treatment of migraine
KR100752549B1 (ko) * 2001-09-28 2007-08-30 에프. 호프만-라 로슈 아게 카르베딜올의 유사다형태
RU2340619C2 (ru) 2002-06-21 2008-12-10 Сувен Лайф Сайенсиз Лимитед Новые тетрациклические арилсульфонилиндолы с аффинностью к серотониновым рецепторам, пригодные в качестве лекарственных средств, способ их получения и содержащие их фармацевтические композиции
EP1537113B9 (en) 2002-06-21 2010-05-26 Suven Life Sciences Limited Arylalkyl indoles having serotonin receptor affinity useful as therapeutic agents, process for their preparation and pharmaceutical compositions containing them
ES2425143T3 (es) 2002-11-28 2013-10-11 Suven Life Sciences Limited N-Arilsulfonil-3-aminoalcoxiindoles
US7875605B2 (en) 2002-11-28 2011-01-25 Suven Life Sciences Limited N-arylsulfonyl-3-substituted indoles having serotonin receptor affinity, process for their preparation and pharmaceutical composition containing them
KR100739987B1 (ko) 2002-12-18 2007-07-16 수벤 라이프 사이언시스 리미티드 세로토닌 수용체 친화력을 가지는 테트라사이클릭 3-치환인돌
RU2430088C2 (ru) * 2004-07-14 2011-09-27 Центарис Гмбх Производные тетрагидрокарбазола и фармацевтическая композиция на их основе
US7601856B2 (en) 2006-07-27 2009-10-13 Wyeth Benzofurans as potassium ion channel modulators
CN101500996B (zh) * 2006-08-07 2012-07-04 埃科特莱茵药品有限公司 (3-胺基-1,2,3,4-四氢-9h-咔唑-9-基)-乙酸衍生物
SI2124556T1 (sl) 2006-10-09 2015-01-30 Charleston Laboratories, Inc. Farmacevtske sestave
ES2691033T3 (es) 2007-02-11 2018-11-23 Map Pharmaceuticals Inc. Método de administración terapéutica de DHE para activar el alivio rápido de la migraña a la vez que se reduce al mínimo el perfil de los efectos secundarios
US20090069399A1 (en) * 2007-09-12 2009-03-12 Protia, Llc Deuterium-enriched frovatriptan
EP2240022B1 (en) 2008-01-09 2016-12-28 Charleston Laboratories, Inc. Bilayered tablets comprising oxycodone and promethazine
WO2010073253A1 (en) * 2008-12-22 2010-07-01 Natco Pharma Limited Method for preparing an optically active frovatriptan
EP3311667A1 (en) 2009-07-08 2018-04-25 Charleston Laboratories, Inc. Pharmaceutical compositions
US9204906B2 (en) 2009-10-22 2015-12-08 Nuvasive, Inc. Posterior cervical fusion system and techniques
US10098674B2 (en) 2009-10-22 2018-10-16 Nuvasive, Inc. System and method for posterior cervical fusion
WO2013016223A2 (en) 2011-07-22 2013-01-31 The University Of Chicago Treatments for migraine and related disorders
US9394314B2 (en) 2012-12-21 2016-07-19 Map Pharmaceuticals, Inc. 8′-hydroxy-dihydroergotamine compounds and compositions
EP2816030A1 (en) 2013-06-20 2014-12-24 Duke Chem, S. A. Process for the preparation of frovatriptan and its enantiomer
GB201312768D0 (en) * 2013-07-17 2013-08-28 Ge Healthcare Ltd Work-up procedure
US10179109B2 (en) 2016-03-04 2019-01-15 Charleston Laboratories, Inc. Pharmaceutical compositions comprising 5HT receptor agonist and antiemetic particulates
EP3766483A1 (en) 2019-07-19 2021-01-20 BioPharma Synergies, S. L. Orodispersible powder composition comprising a triptan
WO2025038666A2 (en) * 2023-08-13 2025-02-20 GATC Health Corp Compounds and methods for treating addiction
CN119499195A (zh) * 2024-11-26 2025-02-25 青岛国信制药有限公司 一种快速吸收琥珀酸呋罗曲坦片及其制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3642816A (en) * 1967-08-10 1972-02-15 Sterling Drug Inc 3-acetamido-1 2 3 4-tetrahydrocarbazole
US4062864A (en) * 1968-01-24 1977-12-13 Sterling Drug Inc. 3-Hydroxy carbazole derivatives
US3959309A (en) * 1968-01-24 1976-05-25 Sterling Drug Inc. 3-Amido-1,2,3,4-tetrahydrocarbazoles
US3592824A (en) * 1970-03-12 1971-07-13 Miles Lab 3-substituted amino-1,2,3,4-tetrahydrocarbazoles
US4172834A (en) * 1971-08-16 1979-10-30 Sterling Drug Inc. 3-Amino-tetrahydrocarbazoles
BE787537A (fr) * 1971-08-16 1973-02-14 Sterling Drug Inc Tetrahydrocarbazoles
DE2815926A1 (de) * 1978-04-13 1979-10-18 Boehringer Mannheim Gmbh Neue carbazolyl-(4)-oxy-propanolamin-derivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
US4257952A (en) * 1977-06-06 1981-03-24 Sterling Drug Inc. 3-Amino-tetrahydrocarbazoles
US4254134A (en) * 1978-03-17 1981-03-03 Endo Laboratories, Inc. Antidepressant 2-amino- and -2-(substituted amino)-cis-hexahydro-carbazoles
EP0115607A1 (de) * 1983-01-04 1984-08-15 MERCK PATENT GmbH Tetrahydrocarbazolderivate

Also Published As

Publication number Publication date
CZ282327B6 (cs) 1997-06-11
CA2113726A1 (en) 1993-01-07
NO934800L (no) 1993-12-23
DK0591280T3 (da) 1999-02-15
ZA924658B (en) 1993-12-24
NO2005011I2 (no) 2008-02-11
HUT68961A (en) 1995-08-28
FI935842A0 (fi) 1993-12-23
AU1977592A (en) 1993-01-25
PL169410B1 (pl) 1996-07-31
JPH06508827A (ja) 1994-10-06
IL102322A0 (en) 1993-01-14
FI935842A7 (fi) 1993-12-23
DE69226953D1 (de) 1998-10-15
PT100620B (pt) 1999-01-29
BR9206237A (pt) 1995-04-11
KR100251571B1 (ko) 2000-07-01
DE10299042I1 (de) 2003-02-20
NL300103I1 (nl) 2002-12-02
AU652842B2 (en) 1994-09-08
SI9200125B (en) 2001-12-31
LU90939I2 (fr) 2002-09-24
PT100620A (pt) 1993-09-30
SK280906B6 (sk) 2000-09-12
IL117104A (en) 1997-09-30
DE10299042I2 (de) 2005-02-03
FI103967B (fi) 1999-10-29
CA2113726C (en) 2008-02-19
IL117105A (en) 1998-01-04
IL117104A0 (en) 1996-06-18
MX9203444A (es) 1993-12-01
UA41254C2 (uk) 2001-09-17
DE69226953T2 (de) 1999-05-12
NO934800D0 (no) 1993-12-23
FI103967B1 (fi) 1999-10-29
CZ150696A3 (en) 1997-06-11
NL300103I2 (nl) 2003-02-03
BR1100460A (pt) 2000-07-18
RU2137474C1 (ru) 1999-09-20
MA22563A1 (fr) 1992-12-31
HK1014669A1 (en) 1999-09-30
CZ286193A3 (en) 1994-07-13
HU218907B (hu) 2000-12-28
CN1034072C (zh) 1997-02-19
AP344A (en) 1994-07-05
US5464864A (en) 1995-11-07
JP3261502B2 (ja) 2002-03-04
SA92130141B1 (ar) 2005-12-18
IE922062A1 (en) 1992-12-30
CZ282061B6 (cs) 1997-05-14
WO1993000086A1 (en) 1993-01-07
PL169392B1 (pl) 1996-07-31
EP0591280A1 (en) 1994-04-13
CZ150596A3 (en) 1997-05-14
AP9200403A0 (en) 1992-07-31
NO304774B1 (no) 1999-02-15
CN1069726A (zh) 1993-03-10
IL102322A (en) 1997-09-30
ATE170746T1 (de) 1998-09-15
NO2005011I1 (no) 2005-05-18
PL171034B1 (en) 1997-02-28
SK131993A3 (en) 1994-06-08
SK280905B6 (sk) 2000-09-12
NZ243288A (en) 1994-09-27
EP0591280B1 (en) 1998-09-09
SK280907B6 (sk) 2000-09-12
SG47877A1 (en) 1998-04-17
US5637611A (en) 1997-06-10
TW214544B (enExample) 1993-10-11
IL117105A0 (en) 1996-06-18
SI9200125A (en) 1992-12-31
CZ282083B6 (cs) 1997-05-14

Similar Documents

Publication Publication Date Title
CY2134B1 (en) Medicaments
ZA924658B (en) Medicaments
AP9100339A0 (en) Medicaments
GB9121204D0 (en) Medicament
GB9115740D0 (en) Medicaments
GB9121463D0 (en) Medicament
GB9122051D0 (en) Medicines
GB9104650D0 (en) Medicaments
GB9108348D0 (en) Medicaments
ZA927925B (en) Medicaments
GB9126027D0 (en) Medicaments
GB9126378D0 (en) Medicaments
GB9117943D0 (en) Medicaments
GB9122472D0 (en) Medicaments
GB9113377D0 (en) Medicaments
GB9113788D0 (en) Medicaments
GB9113383D0 (en) Medicaments
GB9113381D0 (en) Medicaments
GB9113379D0 (en) Medicaments
GB9122475D0 (en) Medicaments
GB9112675D0 (en) Medicaments
GB9112539D0 (en) Medicaments
GB9111901D0 (en) Medicaments
GB9110816D0 (en) Medicaments
GB9109913D0 (en) Medicaments